Prognostic Significance of MYC Rearrangement and Translocation Partner in Diffuse Large B-Cell Lymphoma: A Study by the Lunenburg Lymphoma Biomarker Consortium
| العنوان: | Prognostic Significance of MYC Rearrangement and Translocation Partner in Diffuse Large B-Cell Lymphoma: A Study by the Lunenburg Lymphoma Biomarker Consortium |
|---|---|
| المؤلفون: | Shuchun Zhao, Eva Hoster, C. Burton, Marie José Kersten, Birgitta Sander, Norbert Schmitz, Anton Hagenbeek, John G. Gribben, Daphne de Jong, Mad-Hélénie Elsensohn, Delphine Maucort-Boulch, Laurie H. Sehn, Sharon Barrans, Ekaterina S. Jordanova, Marita Ziepert, Eva Kimby, Gilles Salles, Wolfram Klapper, Randy D. Gascoyne, Maryse Baia, Christiane Copie-Bergman, Wendy Stevens, Daniel Painter, Thierry Jo Molina, Ranjana H. Advani, Maria Calaminici, Alexandra Smith, Susanne Bens, J M Raemaekers, Fabrice Jardin, Luu Pham, Philippe Gaulard, Reiner Siebert, David Scott, Yaso Natkunam, Andreas Rosenwald |
| المساهمون: | Obstetrics and gynaecology, Amsterdam Reproduction & Development (AR&D), CCA - Cancer biology and immunology, Hematology, Pathology, AGEM - Re-generation and cancer of the digestive system, Institute of Pathology, University of Würzburg = Universität Würzburg, Département de pathologie [Mondor], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Henri Mondor-Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12), Biostatistiques santé, Département biostatistiques et modélisation pour la santé et l'environnement [LBBE], Laboratoire de Biométrie et Biologie Evolutive - UMR 5558 (LBBE), Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Institut National de Recherche en Informatique et en Automatique (Inria)-VetAgro Sup - Institut national d'enseignement supérieur et de recherche en alimentation, santé animale, sciences agronomiques et de l'environnement (VAS)-Centre National de la Recherche Scientifique (CNRS)-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Institut National de Recherche en Informatique et en Automatique (Inria)-VetAgro Sup - Institut national d'enseignement supérieur et de recherche en alimentation, santé animale, sciences agronomiques et de l'environnement (VAS)-Centre National de la Recherche Scientifique (CNRS)-Laboratoire de Biométrie et Biologie Evolutive - UMR 5558 (LBBE), Université de Lyon-Université de Lyon-Institut National de Recherche en Informatique et en Automatique (Inria)-VetAgro Sup - Institut national d'enseignement supérieur et de recherche en alimentation, santé animale, sciences agronomiques et de l'environnement (VAS)-Centre National de la Recherche Scientifique (CNRS), Queen Mary University of London (QMUL), INSERM U955, équipe 9, Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Henri Mondor-Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Henri Mondor-Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12)-Institut Mondor de Recherche Biomédicale (IMRB), Institut National de la Santé et de la Recherche Médicale (INSERM)-IFR10-Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12)-Institut National de la Santé et de la Recherche Médicale (INSERM)-IFR10-Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12), Service de pathologie [CHU Necker], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-CHU Necker - Enfants Malades [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Karolinska Institutet [Stockholm], Department of Hematopathology, Schleswig-Holstein University Hospitals, Radboud University Medical Center [Nijmegen], Génomique et Médecine Personnalisée du Cancer et des Maladies Neuropsychiatriques (GPMCND), Université de Rouen Normandie (UNIROUEN), Normandie Université (NU)-Normandie Université (NU)-Institut National de la Santé et de la Recherche Médicale (INSERM), Department of Internal Medicine III, University of Munich, Department of Internal Medicine I, University Hospital Schleswig-Holstein, Campus Kiel, School of Computing [Dublin], Dublin City University [Dublin] (DCU), Institut Mondor de Recherche Biomédicale (IMRB), Institut National de la Santé et de la Recherche Médicale (INSERM)-IFR10-Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12), Centre de Recherche en Cancérologie de Lyon (UNICANCER/CRCL), Centre Léon Bérard [Lyon]-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Centre National de la Recherche Scientifique (CNRS)-Institut National de la Santé et de la Recherche Médicale (INSERM), Clinical Haematology, Université de Lyon-Université de Lyon-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS) |
| المصدر: | Journal of Clinical Oncology, 37(35), 3359-3368. American Society of Clinical Oncology Journal of Clinical Oncology, 37, 3359 Journal of Clinical Oncology Journal of Clinical Oncology, American Society of Clinical Oncology, 2019, pp.JCO.19.00743. ⟨10.1200/JCO.19.00743⟩ Journal of clinical oncology, 37(35), 3359-3368. American Society of Clinical Oncology Journal of Clinical Oncology, 37, 35, pp. 3359 Journal of Clinical Oncology, 2019, pp.JCO.19.00743. ⟨10.1200/JCO.19.00743⟩ Rosenwald, A, Bens, S, Advani, R, Barrans, S, Copie-Bergman, C, Elsensohn, M-H, Natkunam, Y, Calaminici, M, Sander, B, Baia, M, Smith, A, Painter, D, Pham, L, Zhao, S, Ziepert, M, Jordanova, E S, Molina, T J, Kersten, M J, Kimby, E, Klapper, W, Raemaekers, J, Schmitz, N, Jardin, F, Stevens, W B C, Hoster, E, Hagenbeek, A, Gribben, J G, Siebert, R, Gascoyne, R D, Scott, D W, Gaulard, P, Salles, G, Burton, C, de Jong, D, Sehn, L H & Maucort-Boulch, D 2019, ' Prognostic Significance of MYC Rearrangement and Translocation Partner in Diffuse Large B-Cell Lymphoma: A Study by the Lunenburg Lymphoma Biomarker Consortium ', Journal of Clinical Oncology, vol. 37, no. 35, pp. 3359-3368 . https://doi.org/10.1200/JCO.19.00743 |
| سنة النشر: | 2019 |
| مصطلحات موضوعية: | Oncology, Cancer Research, medicine.medical_specialty, Context (language use), [SDV.CAN]Life Sciences [q-bio]/Cancer, 03 medical and health sciences, All institutes and research themes of the Radboud University Medical Center, 0302 clinical medicine, Internal medicine, hemic and lymphatic diseases, medicine, Prospective cohort study, Survival rate, ComputingMilieux_MISCELLANEOUS, business.industry, [SDV.BBM.BM]Life Sciences [q-bio]/Biochemistry, Molecular Biology/Molecular biology, Gene rearrangement, medicine.disease, BCL6, 3. Good health, Lymphoma, 030220 oncology & carcinogenesis, Rituximab, business, Diffuse large B-cell lymphoma, Rare cancers Radboud Institute for Health Sciences [Radboudumc 9], 030215 immunology, medicine.drug |
| الوصف: | PURPOSE MYC rearrangement ( MYC-R) occurs in approximately 10% of diffuse large B-cell lymphomas (DLBCLs) and has been associated with poor prognosis in many studies. The impact of MYC-R on prognosis may be influenced by the MYC partner gene (immunoglobulin [IG] or a non-IG gene). We evaluated a large cohort of patients through the Lunenburg Lymphoma Biomarker Consortium to validate the prognostic significance of MYC-R (single-, double-, and triple-hit status) in DLBCL within the context of the MYC partner gene. METHODS The study cohort included patients with histologically confirmed DLBCL morphology derived from large prospective trials and patient registries in Europe and North America who were uniformly treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone therapy or the like. Fluorescence in situ hybridization for the MYC, BCL2, BCL6, and IG heavy and light chain loci was used, and results were correlated with clinical outcomes. RESULTS A total of 5,117 patients were identified of whom 2,383 (47%) had biopsy material available to assess for MYC-R. MYC-R was present in 264 (11%) of 2,383 patients and was associated with a significantly shorter progression-free and overall survival, with a strong time-dependent effect within the first 24 months after diagnosis. The adverse prognostic impact of MYC-R was only evident in patients with a concurrent rearrangement of BCL2 and/or BCL6 and an IG partner (hazard ratio, 2.4; 95% CI, 1.6 to 3.6; P < .001). CONCLUSION The negative prognostic impact of MYC-R in DLBCL is largely observed in patients with MYC double hit/triple-hit disease in which MYC is translocated to an IG partner, and this effect is restricted to the first 2 years after diagnosis. Our results suggest that diagnostic strategies should be adopted to identify this high-risk cohort, and risk-adjusted therapeutic approaches should be refined further. |
| وصف الملف: | application/pdf |
| اللغة: | English |
| تدمد: | 0732-183X 1527-7755 |
| URL الوصول: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f187e3c57193c0dd3133eb85e673a4a5 https://research.vumc.nl/en/publications/fc53cf9f-ed1f-4527-82bd-a61e25f84be1 |
| حقوق: | OPEN |
| رقم الأكسشن: | edsair.doi.dedup.....f187e3c57193c0dd3133eb85e673a4a5 |
| قاعدة البيانات: | OpenAIRE |
| تدمد: | 0732183X 15277755 |
|---|